A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving ...

A new study has uncovered why some brain cells are more resistant to Alzheimer’s damage than others. Researchers found a natural cleanup system that helps remove toxic tau protein before it can form ...

Researchers are applying CRISPR-Cas9 as a stoichiometric binding tool to improve NGS library normalization. The ...

Investigators at CHOP and UPenn found that lower cell counts could still be associated with poor outcomes if the cells were ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, today announced the launch of its Early Access Express License, a ...

Regulatory tailwinds and weak earnings set the stage The FDA's draft guidance to speed approval of genome editing and RNA therapies has put CRISPR Therapeutics (CRSP) in focus, even as the company ...

Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage ...

Those who believe in clustered regularly interspaced short palindromic repeats (CRISPR) technology are cheering the recent approval for sickle cell disease by the United States Food and Drug ...

Researchers at Sanofi report that cas-CLOVER (deactivated Cas9 fused to the C-terminus of Clostridium Clo051) gene editing has the potential to notably enhance recombinant protein production in ...

US FDA lifts clinical hold of Intellia Therapeutics’ MAGNITUDE phase 3 trial of nex-z for patients with transthyretin amyloidosis with cardiomyopathy: Cambridge, Massachusetts W ...